Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
FGFR1
Name:
fibroblast growth factor receptor 1
Location:
08p11.23
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT01283945 | Study of Oral Lucitanib E-3810 a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor in Patients With Solid Tumors | View | |
| NCT01861197 | Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer | View | |
| NCT03690115 | Study of Ponatinib Iclusig for Prevention of Relapse After Allogeneic Stem Cell Transplantation Allo-SCT in FLT3-ITD AML Patients | View | |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | View | |
| NCT05997459 | A Single Arm Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant | View | |
| NCT06375642 | A Single Arm Single Centered Phase II Trial on the Combination of Adebrelimab Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | View | |
| NCT01440959 | Dovitinib for ImatinibSumitinib-failed Gastrointestinal Stromal Tumors GIST TKI258 | View | |
| NCT00958971 | Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer | View | |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | View | |
| NCT01752920 | Phase 12 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | View | |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs Fulvestrant Alone in ER Breast Cancer Patients | View | |
| NCT03011372 | A Study to Evaluate the Efficacy and Safety of Pemigatinib INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement - FIGHT-203 | View | |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | View | |
| NCT01791985 | AZD4547 Anastrozole or Letrozole NSAIs in ER Breast Cancer Patients Who Have Progressed on NSAIs RADICAL | View | |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | View | |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations | View | |
| NCT01948141 | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | View | |
| NCT02053636 | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer | View | |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor Lucitanib Given to Patients With AdvancedMetastatic Lung Cancer and FGF VEGF or PDGF Related Genetic Alterations | View | |
| NCT02202746 | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor Lucitanib Given to Patients With Metastatic Breast Cancer | View | |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | View | |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | View | |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer | View | |
| NCT03517956 | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor FGFR-Positive Locally Advanced or Metastatic Solid Tumors | View | |
| NCT04731740 | Pembrolizumab and LenvatinibChemotherapy for Poorly DifferentiatedAnaplastic Thyroid Cancer | View | |
| NCT06378580 | The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma | View | |
| NCT03762122 | Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer SQCLC | View | |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- FUZE Clinical Trial | View | |
| NCT04189445 | Futibatinib in Patients With Specific FGFR Aberrations | View | |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | View | |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | View | |
| NCT01868022 | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor FGF Pathway Signaling | View | |
| NCT06275919 | Regorafenib for Recurrent Grade 2 and 3 Meningioma MIRAGE Trial | View | |
| NCT06592989 | A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET | View | |
| NCT05286437 | Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | View | |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | View | |
| NCT01945164 | XL999 Administered Intravenously to a Subject With Advanced Malignancies | View | |
| NCT01975701 | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | View | |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355 an EcDNA-directed Therapy ecDTx in Subjects with Tumors with Oncogene Amplifications | View | |
| NCT06033287 | Real-World Study on CDK46 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HRHER2- MBC | View | |
| NCT02272998 | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes FGFR1 FGFR2 FGFR3 FGFR4 RET KIT | View | |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | View | |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | View | |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | View | |
| NCT02299141 | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | View | |
| NCT02558387 | Trial of BIBF1120 Nintedanib in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck | View | |
| NCT03410693 | Study of Rogaratinib BAY1163877 vs Chemotherapy in Patients With FGFR Fibroblast Growth Factor Receptor-Positive Locally Advanced or Metastatic Urothelial Carcinoma | View | |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR12 Overexpression | View |